Companies /Healthcare

Vanda Pharmaceuticals Inc

NASDAQ: VNDA Biotechnology
$3.84
▲ $0.03 (+0.67%) today
Markets open · 3:51pm ET

VNDA at a Glance

Valuation
Market cap
$230.4M
Profitability
Revenue (TTM)
$229.3M
Profit margin
-119.9%
EPS (TTM)
$-4.62
Price
52-week range
$4 – $10
Street target
$11.50
Earnings
Next report
Feb 9, 2027

Headquartered in Washington, DC Fiscal year ends December NASDAQ: VNDA vandapharma.com

About Vanda Pharmaceuticals

Vanda Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for areas of high unmet medical need, mainly in psychiatry, sleep disorders, neurology, gastrointestinal conditions and immunology.

Its marketed U.S. products are:
- **Fanapt (iloperidone):** an atypical antipsychotic for schizophrenia and bipolar disorder, and the largest revenue contributor.
- **HETLIOZ (tasimelteon):** a melatonin receptor agonist for circadian rhythm sleep disorders.
- **PONVORY (ponesimod):** a treatment for relapsing multiple sclerosis.
- **NEREUS (tradipitant):** an NK-1 receptor antagonist launched in Q2 2026 for prevention of vomiting induced by motion, sold direct-to-consumer and through sales force promotion.

BYSANTI (milsaperidone) was FDA-approved in Q1 2026 for bipolar I disorder and schizophrenia, with launch expected in Q4 2026. It is also in Phase III for adjunctive treatment of major depressive disorder.

Other late-stage programs include:
- **Quimilza (imsidolimab):** an IL-36 receptor antibody under FDA review for generalized pustular psoriasis.
- **NEREUS:** label expansion planned for GLP-1 receptor agonist-induced vomiting.
- **HETLIOZ:** label expansions planned for Delayed Sleep-Wake Phase Disorder and pursued for jet lag disorder and insomnia.

Vanda also pursues regulatory and legal challenges against FDA decisions on several of its applications. Updated

Latest Activity

VNDAVanda Pharmaceuticals
Q3 2026
EPS
-$0.37
est -$0.68+45.8%
Revenue
$70M
est $69M+1.0%

Vanda's spending fell for the first time as Phase III work wrapped up, with the loss beating expectations and revenue climbing 24% year over year. Management now guides full-year revenue above $240 million, with the BYSANTI launch and a December 12 PDUFA date for Quimilza still ahead.

Quarterly EPS — reported vs estimate

VNDA Coverage

9:11am ET
Health and Healthcare

Vanda Investors Can Sleep Easy With This FDA Approval

Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.

Chris Lange
9:50am ET
Health and Healthcare

Vanda Pharma Nails Midstage Gastroparesis Study

Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.

Chris Lange

Frequently Asked Questions

What does Vanda Pharmaceuticals do?

Vanda Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for areas of high unmet medical need, mainly in psychiatry, sleep disorders, neurology, gastrointestinal conditions and immunology.

What is the VNDA stock price target?

The Wall Street consensus 12-month price target for VNDA is $11.50.